RedHill Biopharma Ltd. Sustainability Profile
RedHill Biopharma Ltd., a prominent biopharmaceutical company headquartered in Israel, focuses on the development and commercialisation of innovative therapies for gastrointestinal diseases and cancer. Founded in 2009, RedHill has made significant strides in the industry, particularly with its core products, which include advanced treatments that leverage unique mechanisms of action to address unmet medical needs. With a strong presence in both the Israeli and international markets, RedHill has established itself as a leader in the biopharma sector. The company’s commitment to research and development has led to notable achievements, including successful clinical trials and strategic partnerships that enhance its market position. RedHill Biopharma continues to push the boundaries of medical science, aiming to improve patient outcomes through its cutting-edge therapies.
DitchCarbon Score
How does RedHill Biopharma Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
RedHill Biopharma Ltd.'s score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
RedHill Biopharma Ltd.'s reported carbon emissions
RedHill Biopharma Ltd., headquartered in Israel (IL), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. As there are no emissions data or reduction initiatives available, it is unclear how RedHill Biopharma Ltd. aligns with industry standards for climate action. The absence of emissions reporting may reflect a broader trend within the biopharmaceutical sector, where companies are increasingly being urged to disclose their environmental impact and set ambitious targets for carbon reduction. In summary, RedHill Biopharma Ltd. has not provided emissions data or climate commitments, indicating a potential area for future development in their sustainability strategy.
How Carbon Intensive is RedHill Biopharma Ltd.'s Industry?
How Carbon Intensive is RedHill Biopharma Ltd.'s Location?
RedHill Biopharma Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
RedHill Biopharma Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
